Risk Sciences International (RSI) |

McLaughlin Centre for Population Health Risk Assessment

University of Ottawa
Pharmacovigilance Workshop

Tabaret Hall, 550 Cumberland Street, Room 083

Friday, January 26, 2007
Pharmacovigilance in Canada

Get Final Program

Get Proceedings

Get Workshop Summary

Workshop Particpants

View List

8:45am
Welcome and Introduction
Daniel Krewski, PhD, MHA, Professor and Director McLaughlin Centre for Population Health Risk Assessment, University of Ottawa & President and CEO Risk Sciences International (RSI)
cphra@uottawa.ca

9:00am
Adverse Drug Reaction Reporting and Signal Detection in Canada
Heather Sutcliffe, Health Canada, Director Marketed Health Products Safety and Effectiveness Information Bureau (MHPSEIB)
MHPD_DPSC@hc-sc.gc.ca

9:30am
Future Directions in the Review of Post-Market Safety Data, Sources of Evidence and Risk Assessment Tools
Lucye Galand, Health Canada, Manager, Scientific Section, Marketed Pharmaceuticals and Medical Devices Bureau
MHPD_DPSC@hc-sc.gc.ca

10:00am
Risk Communication for Marketed Health Products
Cindy Evans, Health Canada, A/Director, Therapeutic Effectiveness and Policy Bureau
MHPD_DPSC@hc-sc.gc.ca

10:45am
The Future of Drug Safety
David Korn, MD, Senior Vice President, Biomedical and Health Sciences Research, Association of American Medical Colleges & Member IOM Committee on the Assessment of the US Drug Safety System
dkorn@aamc.org

11:30am
Knowledge Findings for Globally Important ADR Signals
I. Ralph Edwards, Professor and Director WHO Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre, Sweden

1:15pm
Pharmaceutical Use in Pregnancy
Mark Walker MD, Associate Professor, University of Ottawa & Scientist Ottawa Health Research Institute (OHRI)
mwalker@ohri.ca

1:35pm
Pharmacoepidemilogy
C. Ineke Neutel, PhD, FACE, FISPE, University of Ottawa
cneutel@uottawa.ca

1:55pm
Spontaneous Adverse Drug Reaction Report Data and Their Potential for Safety Knowledge Discovery
Alex Ruggieri, MD MHS, Healthcare Executive, Chief Medical Officer and Senior Director for Safety Solutions, Cerner Galt
Alex.Ruggieri@Cerner.com

2:15pm
HealthFactsTM Datawarehouse & Active Pharmacovigilance
Doug McNair MD PhD, Sr. Vice President Cerner LifeSciences
DMCNAIR@CERNER.COM

2:45pm
Panel Discussion «Role of Academia in Pharmacovigilance in Canada »

Panel Chair: Colleen Metge, BSc (Pharm), PhD, Associate Professor, Faculty of Pharmacy, University of Manitoba

Panel Members:
Mark Walker MD, Associate Professor, University of Ottawa & Scientist Ottawa Health Research Institute (OHRI)
Anthony Krantis PhD, Professor, Cellular & Molecular Medicine, Director, Centre for Research in Biopharmaceuticals & Biotechnology (CRBB), Co-Director BIOMECanada Canadian ICC Research Network
akrantis@uottawa.ca
Sam Kacew PhD, Professor, Cellular & Molecular Medicine
sam.kacew@uottawa.ca
David Clapin, PhD, Branch Science Advisor, Health Canada, Science Coordination and Policy Division
David_Clapin@hc-sc.gc.ca

4:00pm
Pharmacovigilance Workshop Summary
Daniel Krewski, PhD, MHA, Professor and Director McLaughlin Centre for Population Health Risk Assessment, University of Ottawa & CEO Risk Sciences International (RSI)

Adjourn

Online presentations from the Pharmacovigilance Workshop are subject to copyright protection. Permission from the speaker is required prior to any copying, reproducing, or rebroadcasiting any portion of the speaker’s presentations.


Workshop Steering Committee
Daniel Krewski, PhD, MHA, Professor and Director McLaughlin Centre for Population Health Risk Assessment, University of Ottawa & CEO Risk Sciences International (RSI)
Daniel Bedard, MSc, Research Coordinator, McLaughlin Centre for Population Health Risk Assessment, University of Ottawa
Vicky Hogan, Risk Process Manager, Office of Risk Management, Health Canada
Doug McNair, MD, PhD, Sr. Vice President Cerner LifeSciences